^
CANCER:

Ovarian Serous Adenocarcinoma

Related cancers:
BRAF V600E
Ovarian Serous Adenocarcinoma
encorafenib + binimetinib
Sensitive: C1 - Off-label
BRCA2 mutation
Ovarian Serous Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
BRCA1 mutation
Ovarian Serous Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
BRCA1 mutation
Ovarian Serous Adenocarcinoma
olaparib + LY2606368
Sensitive: C2 – Inclusion Criteria
KRAS G12D
Ovarian Serous Adenocarcinoma
VS-6766 + VS-6063
Sensitive: C3 – Early Trials
KRAS G12A
Ovarian Serous Adenocarcinoma
VS-6766 + VS-6063
Sensitive: C3 – Early Trials
KRAS G12V
Ovarian Serous Adenocarcinoma
VS-6766 + VS-6063
Sensitive: C3 – Early Trials
Choline elevation
Ovarian Serous Adenocarcinoma
pembrolizumab
Sensitive: C3 – Early Trials
BRCA1 mutation
Ovarian Serous Adenocarcinoma
AZD1775
Sensitive: C4 – Case Studies
GOPC-ROS1 fusion
Ovarian Serous Adenocarcinoma
crizotinib
Sensitive: C4 – Case Studies
ER Y537N
Ovarian Serous Adenocarcinoma
fulvestrant
Sensitive: C4 – Case Studies
TMB-H + MSH6 F1088fs
Ovarian Serous Adenocarcinoma
pembrolizumab
Sensitive: C4 – Case Studies
BRCA2 mutation
Ovarian Serous Adenocarcinoma
LY2606368 + LY3023414
Sensitive: D – Preclinical
BRAF L485-P490 deletion
Ovarian Serous Adenocarcinoma
LY3009120
Sensitive: D – Preclinical
PRMT1 underexpression
Ovarian Serous Adenocarcinoma
carboplatin
Sensitive: D – Preclinical
PRMT1 underexpression
Ovarian Serous Adenocarcinoma
cisplatin
Sensitive: D – Preclinical